What is the role of MIB-1 testing in response to therapy assessment for ovarian cancer?

Updated: Aug 10, 2020
  • Author: Andrew E Green, MD; Chief Editor: Yukio Sonoda, MD  more...
  • Print

MIB1-determined tumor growth fraction has been studied as an additional tool for the decision of adjuvant therapy in patients with very early stages of ovarian carcinomas. In one study, MIB1 predicted tumor recurrences in 84% of the ovarian cancers. [93]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!